Mai H. Le

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

Christopher Garris, Sean P. Arlauckas, Rainer H. Köhler et al. · Immunity · 2018 · 937 citations · Full text

Medicine, Immunology, Oncology +12

Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397

Catherine C. Smith, Chao Zhang, Kimberly C. Lin et al. · Cancer Discovery · 2015 · 203 citations · Full text

Medicine, Medicinal Chemistry, Oncology +13

Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors

Robert Wesolowski, Neelesh Sharma, Laura Reebel et al. · Therapeutic Advances in Medical Oncology · 2019 · 169 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

Alain P. Algazi, Chris Twitty, Katy K. Tsai et al. · Clinical Cancer Research · 2020 · 146 citations · Full text

Life Sciences, Immunology, Oncology +17

Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients

Alain P. Algazi, Shailender Bhatia, Sanjiv S. Agarwala et al. · Annals of Oncology · 2020 · 135 citations · Full text

Medicine, Immunology, Oncology +17